Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.04% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Axonics Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Axonics Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Non-Reccuring Items
-$13.5m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Non-Reccuring Items
-$465m
CAGR 3-Years
-22%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Non-Reccuring Items
-$167m
CAGR 3-Years
34%
CAGR 5-Years
-5%
CAGR 10-Years
13%
Stryker Corp
NYSE:SYK
Non-Reccuring Items
-$466m
CAGR 3-Years
23%
CAGR 5-Years
11%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Non-Reccuring Items
-$252m
CAGR 3-Years
-24%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Non-Reccuring Items
-$4.2m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

AXNX Intrinsic Value
33.99 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Axonics Inc's Non-Reccuring Items?
Non-Reccuring Items
-13.5m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Non-Reccuring Items amounts to -13.5m USD.

What is Axonics Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-45%

Over the last year, the Non-Reccuring Items growth was 32%. The average annual Non-Reccuring Items growth rates for Axonics Inc have been -45% over the past three years .

Back to Top